Recombinant Antibody Production

This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open basis with Genscript USA Inc, Piscataway, NJ to produce recombinant human antibodies against Influenza A.
GenScript has previously provided this service for the laboratory. The same produced antibodies, from the same vendor, warrants scientific integrity for downstream experiments. This supports the mission of the Cellular Biology Section of NIH.

Place of Performance is Bethesda, MD 20892.

The statutory authority for this sole source requirement is 41 U.S.C. 253 (c) (1) as implemented by FAR 6.302-1 only one responsible source and no other supply of service will satisfy agency requirements. THIS IS NOT A REQUEST FOR PROPOSAL. All responsible sources that could provide comparable services may submit a capability statement that will be considered by email (subject line to reference NOI-RML-D-1927543) to Bevin Feutrier, bevin.feutrier@nih.gov by 5:00 pm eastern standard time September 09, 2018. All responses received by the closing date of this synopsis will be considered by the Government. A determination not to compete this requirement, based upon responses to this notice, is solely within the discretion of the Government.

.